J. Kearns

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “The validation of new CHD1L inhibitors as a therapeutic strategy for cancer”.

The validation of new CHD1L inhibitors as a therapeutic strategy for cancer

Biomedicine & Pharmacotherapy(2023)10.1016/j.biopha.2023.116037

N/A

0.330DataRank · unranked

8 citations

Paul Awolade, Qiong Zhou, Hector Esquer, Brock Matter, J. Kearns +5 more

CHD1L Regulates Cell Survival in Breast Cancer and Its Inhibition by OTI-611 Impedes the DNA Damage Response and Induces PARthanatos

International Journal of Molecular Sciences(2024)10.3390/ijms25168590

N/A

0DataRank · unranked

6 citations

Hector Esquer, Timothy Kellett, J. Kearns, Paul Awolade, Qiong Zhou +2 more